Immunotherapy of a carcinogen-induced murine sarcoma with soluble tumor-specific transplantation antigens.

Abstract

Tumor-specific transplantation antigens (TSTA), extracted from the 3-methylcholanthrene-induced sarcoma MCA-F and partially purified by flat-bed isoelectric focusing, were used to treat syngeneic inbred C3H/HeJ mice bearing supralethal neoplastic challenges. Three weekly injections of 25 micrograms TSTA increased the survival times of hosts inoculated 1 day earlier with ten times the lethal dose of MCA-F cells. In another protocol TSTA injections decreased the incidence and outgrowth of a local metastasis in mice given sc supralethal inoculations and completely resected of established 1-cm tumors. In addition, weekly injections of 25 micrograms MCA-F TSTA decreased the tumor recurrence rate and increased the survival times of hosts with recurrent neoplastic disease by virtue of residual tumor cells following resection of 2-cm masses. The therapeutic effect of TSTA was immunologically specific: Animals cured of local MCA-F recurrences promptly died from primary challenge with the non-cross-reacting sarcoma MCA-D. The results suggest that active specific immunotherapy may represent a useful adjunct to treatment of hosts bearing modest tumor burdens.

• Authors: B D Kahan, T Tanaka, N R Pellis
• Journal: Journal of the National Cancer Institute (J Natl Cancer Inst) Vol. 65 Issue 5 Pg. 1001-4 (Nov 1980) ISSN: 0027-8874 [Print] United States
• PMID: 6159495 (Publication Type: Journal Article)

Chemical References

• Antigens, Neoplasm
• Epitopes
• Histocompatibility Antigens
• Methylcholanthrene

Topics

• Animals
• Antigens, Neoplasm (administration & dosage)
• Epitopes
• Female
• Histocompatibility Antigens (administration & dosage)
• Immunotherapy
• Methylcholanthrene
• Mice
• Mice, Inbred Strains
• Neoplasm Recurrence, Local
• Sarcoma, Experimental (chemically induced, immunology, therapy)